![]() |
|
|
Vol. 293, Issue 3, 1074-1083, June 2000
Departments of Pharmacology and Toxicology (K.R.B., H.R.B.) and Pathology and Laboratory Medicine (V.P.), Indiana University School of Medicine, Indianapolis, Indiana; Department of Chemistry, the University of the West Indies, St. Augustine, Trinidad and Tobago (A.M.); and Department of Chemistry, University of Toronto, Ontario, Canada (W.F.R.)
| |
Abstract |
|---|
|
|
|---|
The isoflavones tectoridin (TTR) and 3'-hydroxy TTR (3'-TTR) were isolated from an Ayurvedic herbal preparation Vacä and evaluated for their affinity and effect on ryanodine receptors (RyR) using junctional sarcoplasmic reticulum vesicles (JSRVs). In [3H]ryanodine displacement binding affinity assays, TTR and 3'-TTR exhibited IC50 values of 17.3 ± 1.3 µM (Kd = 6.7 ± 0.4 µM) and 6.6 ± 1.4 µM (Kd = 2.4 ± 0.2 µM), respectively, for fast skeletal muscle RyR (RyR1) compared with an IC50 value for ryanodine of 6.2 ± 0.4 nM (Kd = 2.4 nM). TTR demonstrated a 3-fold higher affinity for cardiac RyR (RyR2) [IC50 value of 5.2 ± 0.6 µM (Kd = 0.95 ± 0.3 µM)] than for RyR1. The displacement isotherms for both TTRs paralleled that for ryanodine, consistent with the notion that all three are likely binding to similar site(s) on the receptors. Calcium efflux from and calcium influx into JSRVs were used to measure function effects of TTRs on binding to RyR. In calcium efflux assays, TTR (up to 1 mM) enhanced the release of 45Ca2+ from JSRVs in a concentration-dependent manner (EC50act of 750 µM). Higher concentrations deactivated (partially closed) RyR1. 3'-TTR had similar effects, but was approximately 2-fold more potent, exhibiting an EC50act value of 480 µM. Using passive calcium influx assays, TTR activated and deactivated RyR1 in a time- and concentration-dependent manner. The aglycone tectorigenin also was effective in displacing [3H]ryanodine from RyR1 but not from RyR2. These results demonstrate that TTRs are capable of interacting at ryanodine binding sites to differentially modulate fast skeletal and cardiac calcium-release channels.
| |
Introduction |
|---|
|
|
|---|
Release
of calcium ions from internal sarcoplasmic reticulum (SR) is a key step
in the cascade of events leading to striated muscle contraction
(Berridge, 1997
; Franzini-Armstrong and Protasi, 1997
). Of the two
types of calcium-release channels present on SR, namely inositol
1,4,5-trisphosphate receptors and ryanodine receptors (RyR), the
latter is the major calcium-release channel involved in
excitation-contraction coupling (Bers, 1991
; Catterall, 1991
). Thus,
regulating RyR may be a strategy for beneficially altering the
concentrations of intracellular calcium.
The plant alkaloid ryanodine is the best known exogenous ligand of RyR.
At the single channel level, its effects are quantal, occurring in
three discrete steps. Nanomolar concentrations increase open
probability without changing conductance, low micromolar concentrations
reduce conductance but increase open probability (modified state), and
higher concentrations of the alkaloid lead to irreversible channel
closure (Holmberg and Williams, 1990
; Buck et al., 1992
).
Similar effects are also observed at the multichannel level (using SR
membrane vesicles) where low concentrations of ryanodine activate or
open RyR, whereas higher concentrations deactivate or close them
(Lattanzio et al., 1987
; Humerickhouse et al., 1993
). Ryanodine cannot
be considered a therapeutic lead compound because it activates and
deactivates RyR at relatively similar concentrations and it is
extremely toxic (Waterhouse et al., 1987
; Besch et al., 1994
). Also,
its complex structure (heptacyclic, polyhydroxy diterpene)
limits facile chemical synthesis; to date, only its less active
C3 epimer has been produced (Ruest and
Deslongchamp, 1993
). The need to identify additional compounds with
ryanodine-like actions, but simpler pharmacodynamics and chemical
structures, is warranted.
In the Ayurvedic literature, ground rhizomes of Acorus
calamus Linn (referred to as Vacä) are indicated for
treatment of the symptoms of several illnesses including inflammation
and constipation. Vacä is also used as an expectorant, stomachic,
and anticonvulsant (Nadkarni, 1954
). Recently, Panchal et al.
(1989)
showed that ethanolic extracts of rhizomes of Acorus
calamus Linn provided protection against strychnine-induced
convulsions in frogs. These researchers also found that extracts of
Acorus calamus Linn produce negative chronotropic and
inotropic effects in frog hearts. Neither the mechanism(s) underlying
the decrease in rate and force of cardiac contractions nor the
component(s) responsible for these effects has yet been defined.
Some years ago, we reported that at low concentrations (
1 µM),
ryanodine induces transient negative inotropic effects on cat
ventricular papillary muscles (Sutko et al., 1979
). Very recently, Ju
and Allen (1999)
showed biphasic chronotropic effects of
ryanodine on bullfrog cardiac nodal tissue. Based on these reports, we
hypothesized that the negative inotropic and chronotropic effects of
extracts of Acorus calamus Linn on cardiac muscle might be
attributable to component(s) with ryanodine-like actions.
This study was undertaken to isolate principal constituents from extracts of Acorus calamus Linn that may bind to and functionally modulate calcium flux via RyR calcium-release channels.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials
Ryanodine used in this study was isolated from chipped
Ryania wood supplied by Integrated Biotechnology Corporation
(Carmel, IN) and purified by chromatography to
98% (Bidasee et al.,
1993). Ground rhizomes of Acorus calamus Linn were
obtained from Star West Botanical Inc. (Rancho Cordova, CA) in 1993 under the label Vacä. [3H]Ryanodine
(specific activity 87 Ci/mmol) and
45CaCl2 (specific activity
2.7 Ci/mmol) were purchased from NEN Life Science Products (Boston,
MA). Methohexital sodium (Brevital) was obtained from Eli Lilly & Co.
(Indianapolis, IN). Precoated silica gel plates (with fluorescence
indicator) were obtained from Sigma (St. Louis, MO). All other reagents
and solvents used were of analytical grade.
Isolation and Characterization of Ryanodine-Like Constituents from Vacä
Briefly, 100 g of Vacä was extracted by stirring overnight in 500 ml of ethanol. The next day, the ethanol was filtered and rotary evaporated to dryness to produce 1.1 g of residue. This residue (E1) was dissolved in 50 ml of water and extracted three times with 75 ml of chloroform (CHCl3), each time retaining both the aqueous and organic layers. The pooled aqueous fractions were then freeze-dried, producing 410 mg of a pale yellow powder designated E2w. On rotary evaporation, the CHCl3 extract (E1c) produced 550 mg of an oily liquid.
E2w was separated further into various fractions by redissolving in 2 ml of CHCl3/methanol (MeOH) (90:10) and chromatographing on a silica gel column (50 g). Sequential elution with six solvent combinations of increasing polarity (100 ml each) was as follows: CHCl3 containing 2 drops of triethylamine, the same but with 2% MeOH, 4% MeOH, 6% MeOH, 10% MeOH, and 15% MeOH. Fractions eluted from the column with the latter two solvent combinations were pooled and rotary evaporated to dryness affording 210 mg (E2w1). E2w1 was separated further by semipreparative, high-performance liquid chromatography using MeOH/water (42:58) as the mobile phase into three compounds: E2w1a (~2.0 mg), E2w1b (25 mg), and E2w1c (40 mg). Rf values of these three compounds on thin-layer chromatography (TLC) plates using CHCl3/MeOH/40% aqueous methylamine (85 parts:15 parts:2 drops) as the mobile phase were E2w1a (0.15), E2w1b (0.36), and E2w1c (0.44).
Crystallization of E2w1c from MeOH/CHCl3 (90:10) produced pale white needles, m.p. 250 to 252°C (uncorrected). Melting point of E2w1b (blue-white flakes after freeze-drying from dioxane) was 120°C (uncorrected). Carbon, hydrogen, nitrogen elemental analysis, NMR, and mass spectrometry were used to elucidate the chemical structures of E2w1b and E2w1c.
Preparation of JSRVs from Rabbit Skeletal Muscle (RyR1)
Crude sarcoplasmic reticular membrane vesicles (CVs) were
prepared as described previously (Humerickhouse et al., 1993
, 1994
). Briefly, after induction of anesthesia with methohexital sodium, fast-twitch skeletal muscles (perivertebral and hind limb) from rabbits
were removed, homogenized at speed setting 4.5 with a Kinematica PT-600
homogenizer (Polytron, Patterson, NJ) in isolation buffer [0.3
M sucrose, 10 mM imidazole·HCl, 230 µM phenylmethylsulfonyl fluoride (PMSF), 1.1 µM leupeptin, pH 7.4], and then centrifuged at
7500gav for 20 min. The supernatant
was discarded, and the pellet was resuspended in fresh isolation
buffer, homogenized for a second time at speed setting 5.5, and
centrifuged at 11,000gav for 20 min.
The supernatant was filtered through gauze (cheese cloth), and CVs were
obtained by sedimentation at 85,000gav
for 30 min. The CVs were resuspended in isolation buffer, quick-frozen in dry ice-acetone, and stored at
80°C.
JSRVs were prepared by layering CVs onto discontinuous sucrose
gradients (1.5, 1.2, 1.0, and 0.8 M sucrose in isolation buffer, top to
bottom layers, respectively) and centrifuged at
110,000gav for 2 h. The vesicles
that sedimented to the interface between 1.2 and 1.5 M sucrose were
collected, resuspended in 30 ml of isolation buffer, and harvested by
centrifugation at 110,000gav for
2 h. The resultant pellet was resuspended in fresh isolation buffer, quick-frozen, and stored at
80°C. Protein concentrations were determined later (Lowry et al., 1951
).
Preparation of CVs from Canine Heart (RyR2)
SR membrane vesicles were prepared from canine heart as
described (Humerickhouse et al., 1993
). Briefly, after deep anesthesia with methohexital sodium, hearts were removed from two dogs and placed
into ice-cold saline solution. Ventricular tissues were collected,
stripped of adhering adventitia, and homogenized in a buffer consisting
of 10 mM NaHCO3, 230 µM PMSF, and 1.1 µM
leupeptin, pH 7.4, using a Kinematica PT-600 homogenizer
(Polytron) at a speed setting of 6.0 (3 × 30 s). The
homogenate was then centrifuged twice at low speeds (first at
8,500gav and then at
12,000gav) for 20 min each to remove
mitochondria, nuclei, and other contaminating debris. Crude SR vesicles
were harvested by sedimenting the supernatant at
27,500gav for 30 min. The vesicles
were resuspended in buffer containing 0.6 M KCl, 30 mM histidine, 230 µM PMSF, and 1.1 µM leupeptin, pH 7.4, and then centrifuged at
46,000gav for 30 min. The pellet of
membrane vesicles was resuspended in storage buffer (0.25 M
sucrose, 10 mM histidine, 230 µM PMSF, and 1.1 µM leupeptin, pH
7.4) at a concentration of 8 to 10 mg/ml, quick-frozen, and stored at
80°C until use.
Pharmacological Profiles of Purified Ryanodine-Like Constituents from Vacä
The principal ryanodine-like compounds isolated and characterized from Vacä were the two isoflavones TTR (E2w1c) and its congener 3'-hydroxy TTR (3'-TTR; E2w1b).
Relative Binding Affinity Assays.
The affinities of TTR and
3'-TTR for RyR1 and RyR2 RyR were assessed from their ability to
compete with [3H]ryanodine for binding to these
receptors. Briefly, JSRVs prepared from rabbit fast skeletal muscle or
membrane vesicles from canine ventricular muscle (0.1 mg/ml) were
incubated in binding buffer, called buffer A for later comparison,
consisting of 500 mM KCl, 20 mM Tris·HCl, 0.2 mM
CaCl2, pH 7.4, at 37°C, containing 6.7 nM
[3H]ryanodine with increasing concentrations of
either TTR or 3'-TTR (up to 200 µM) for 2 h at 37°C.
Nonspecific binding was determined simultaneously by incubating
vesicles with 500 µM TTR or 3'-TTR as appropriate. This concentration
of 3'-TTR and TTR was chosen for determining nonspecific binding
because it routinely displaces
96% of
[3H]ryanodine bound to RyR. At the end of the
incubation time, the samples were filtered through GF/C filters
(0.45 µ; Whatman International, Maidstone, England) using a cell
harvester (model M-24R; Brandel Biomedical Research, Gaithersburg, MD),
and the vesicles remaining on the filter paper were washed three times
with 3 ml of ice-cold binding buffer (pH 7.4 at 0°C). The filters
were then placed in scintillation cocktail, vortexed, and allowed to
stand overnight before liquid scintillation counting to determine the
amount of [3H]ryanodine bound. This protocol
was chosen for equilibrium displacement binding, because in previous
studies, we found under these conditions that >80% of
Ca2+-dependent ryanodine binding to RyR occurred
(Bidasee et al., 1994
; Emmick et al., 1994
). Also, under these
conditions 6.7 nM [3H]ryanodine binds primarily
to high-affinity ryanodine binding site(s) on RyR (Zhang et al.,
1999
). Displacement curves, IC50, and
Kd values were calculated using the
binding analysis programs PrismPad 2.0 (PrismPad Software Inc.,
San Diego, CA) and EBDA/Ligand (MacPherson, 1985
). For comparison,
displacement binding with the prototype drug ryanodine was run
concurrently in each assay.
Passive calcium efflux assays.
JSRVs prepared from
rabbit fast skeletal muscles (3.5 mg/ml) were preincubated for 2 h
at 22°C in calcium loading buffer [140 mM NaCl, 20 mM HEPES, 1.1 mM
Ca2+ (spiked with 0.25 µM
45Ca2+), 0.1 mM EGTA, and 1 mM MgCl2, pH 7.0 at 22°C] in the presence of
varying concentrations of TTR and 3'-TTR (up to 5 mM). At the end of
the preincubation, passive calcium
(45Ca2+) efflux through
RyR1 was determined by diluting the vesicles (5 µl) 100-fold into an
efflux buffer (140 mM NaCl, 20 mM HEPES, 0.2mM
Ca2+, 1 mM EGTA, and 1 mM
MgCl2, pH 7.0 at 22°C). Efflux was allowed to
continue for 3 s and then stopped by additionally diluting the
vesicles 6-fold into an ice-cold stop solution (140 mM NaCl, 20 mM
HEPES, 0.1 mM EGTA, 5 mM MgCl2, 25 µM ruthenium
red, and 250 µM LaCl3) and rapidly
filtering. The vesicles on the filters were then washed three times
with 3 ml of rinse solution (identical with stop solution except
without ruthenium red), and the
45Ca2+ remaining inside the
vesicles was determined by liquid scintillation counting. In this
assay, the amount of calcium efflux occurring through RyR1 in 3 s
is inversely related to the amount of calcium (45Ca2+) remaining in the
vesicles. Because calcium efflux may be different from different
vesicular preparations (reflecting, for example, different densities of
RyR), drug-induced releases were taken as those greater than the amount
released in the absence of TTR and 3'-TTR. For comparison,
ryanodine-induced calcium releases from JSRV preparations were
conducted in parallel. Maximum releasable calcium (full agonist
efficacy) was defined as before (Bidasee and Besch, 1998
) from the
amount of release that occurs in the presence of 60 µM
C10-Oeq guanidinopropionyl
ryanodine and 1 mM
,
-methylene adenosine 5'-triphosphate
(AMP-PCP) determined for each vesicle preparation.
Passive calcium influx assays.
To further characterize the
deactivating (partial channel closing) effects of TTR on its binding to
RyR1, we developed and used passive calcium influx assays (Besch et
al., 1995
). Briefly, JSRVs (5.0 mg/ml) were resuspended in binding
buffer called buffer B (250 mM KCl, 15 mM NaCl, 20 mM HEPES, 25 µM
CaCl2, pH 7.0) along with either 6.0, 60, or 600 µM TTR. The samples were then incubated for up to 3 h at 37°C.
After various incubation times (5, 10, 15, 30, 60, and 120 min),
aliquots of the vesicles (5 µl) were diluted 100-fold into an influx
buffer (250 mM KCl, 15 mM NaCl, 20 mM HEPES, 0.5 mM
CaCl2, 0.125 µM
45Ca2+, and 0.1 mM EGTA),
and calcium influx was allowed to proceed for 5 s. This provides
time-effect data by giving a snapshot of the ensemble patency of RyR1
channels that had been achieved during varying preincubation periods.
Additional influx was terminated immediately by diluting the JSRVs
6-fold into an ice-cold stop solution (250 mM KCl, 15 mM NaCl, 20 mM
HEPES, 0.1mM EGTA, 5 mM MgCl2, 25 µM ruthenium
red, and 250 µM LaCl3) and rapidly filtering. The vesicles were then washed three times with 3 ml of the stop buffer,
and 45Ca2+ content inside
the vesicles was determined by liquid scintillation counting.
Nonspecific influx was determined by identical incubation of JSRVs in
binding buffer to which 25 µM ruthenium red and 250 µM
LaCl3 had been added before initiation of the
preincubation. In this assay, the amount of calcium
(45Ca2+) fluxed into the
vesicles is related directly to the ensemble functional patency
(openness) of RyR1 when the snapshot is taken; the greater the amount
of calcium (45Ca2+) found
inside the vesicles, the more activated (opened) the RyR1 had been and
vice versa.
| |
Results |
|---|
|
|
|---|
Isolation and Identification of Ryanodine-Like Constituents from Vacä
During a preliminary screen, we found that an ethanol extract of the Acorus calamus Linn obtained under the Ayurvedic label, Vacä, displaced [3H]ryanodine from RyR1 in a concentration-dependent manner. We then set out to isolate and characterize the constituent(s) in this extract (E1) of Vacä responsible for this activity.
E1 contained several UV-active (365 nm) compounds with TLC
Rf values ranging from 0.3 to 0.9. The less
polar of these compounds (TLC Rf
0.7) were
removed by dissolving E1 in water and then extracting it with
chloroform. The major components of E1c were cis/trans-asarones (by comparison with
authentic cis/trans-asarones) and in binding
affinity; up to a concentration of 1000 µg/ml, these compounds did
not demonstrate the ability to displace
[3H]ryanodine from RyR1 (data not shown). We
have not yet identified the other minor compounds present in
E1c, although they also are likely to be essential oils (Mazza, 1985
).
Analysis of the water-soluble components of Vacä (from ethanol
extracts that had been previously extracted with chloroform (designated
E2w) revealed the presence of three major UV-active compounds with
Rf values on TLC plates of 0.15, 0.36, and 0.44. Using reversed-phase (C18)
high-performance liquid chromatography, we isolated and purified
these three compounds and assigned them the labels E2w1a (2 mg), E2w1b
(40 mg), and E2w1c (25 mg), respectively. Using carbon, hydrogen,
nitrogen elemental analysis, 1H and
13C NMR spectrometry and mass spectrometry, E2w1c
and E2w1b were identified as the isoflavones TTR
(4H-1-benzopyran-4-one-3-(4'-hydroxy-phenyl)-5-hydroxy-6-methoxy-7-(
-D-glucopyranosyloxy) and its congener 3'-TTR (4H-1-benzopyran-4-one-3-(3',
4'-dihydroxy-phenyl)-5-hydroxy-6-methoxy-7-(
-D-glucopyranosyloxy), respectively (Fig. 1). We have yet to
fully elucidate the structure of E2w1a.
|
Relative Binding Affinities of TTR, 3'-TTR, and Ryanodine for RyR1
The affinities of the aqueous extract Ew2 and its principal
constituents, TTR and 3'-TTR, were determined from their abilities to
compete with 6.7 nM [3H]ryanodine for binding
sites on RyR1, using displacement binding affinity assays (Fig.
2). In preliminary assays, E2w
(water-soluble extract) displaced [3H]ryanodine
from RyR1 binding site(s) in a concentration-dependent manner
exhibiting an IC50 value of 18 ± 2.0 µg/ml (Fig. 2,
). From this crude extract, 3'-TTR and TTR were
purified to homogeneity. In displacement binding affinity assays,
3'-TTR (
) and TTR (
) also competed with
[3H]ryanodine from binding sites on RyR1,
exhibiting IC50 values of 3.2 ± 1.1 and
8.0 ± 0.2 µg/ml. Because molecular masses are available for
these compounds, their IC50 values were
calculated as 6.7 ± 1.4 µM (mol. wt. 478) and 17.3 ± 1.3 µM (mol. wt. 462) for 3'-TTR and TTR, respectively. Using the
equation (Cheng and Prusoff, 1973
):
|
(1) |
|
Although both TTR and 3'-TTR display affinities some three orders of magnitude less than that of ryanodine for RyR1, their binding isotherms paralleled that of ryanodine. Their displacement curves also appear saturable, indicating a finite population of high-affinity ryanodine binding site(s).
Relative Binding Affinities of TTR and Ryanodine for RyR2
The affinity of TTR for RyR2 was also estimated using equilibrium
displacement binding affinity assays. As shown in Fig.
3 (
), TTR displaced
[3H]ryanodine from RyR2 with an
IC50 value of 5.2 ± 0.6 µM. Thus, the
affinity of TTR for RyR2 is almost three orders of magnitude less than
that of ryanodine (IC50 of 4.8 ± 0.2 nM and
Kd = 1.2 ± 0.1 nM). Using the
Cheng-Prusoff equation above, TTR exhibits a
Kd value of 0.93 ± 0.3 µM for RyR2.
Its binding isotherm also parallels that of ryanodine, suggesting that
both compounds are binding to similar sites on the receptor. These data
also indicate that TTR has an affinity for RyR2 3.5 times greater than
its affinity for RyR1. Similar characteristics have also been noted
with ryanodine in this as well as in previous studies (Humerickhouse et
al., 1993
). In addition, these data show that TTR displays apparent saturation kinetics, indicating a limited quantity of binding sites on
RyR2 with affinity for isoflavones.
|
Various compounds with conjugated carbonyls (e.g., quinones) are known
to alter the binding of [3H]ryanodine to RyR by
interacting with hyperreactive sulfhydryl groups (oxidation/reduction
reactions) (Abramson et al., 1988
; Feng et al., 1999
). Because TTR
contains a conjugated carbonyl functionality, we sought to determine
whether the decrease in [3H]ryanodine seen with
TTR might be attributable to its ability to interact with sulfhydryl
groups on RyR. The addition of 2 mM reduced glutathione (a nonspecific
sulfhydryl reagent) to the binding buffer had no significant effect on
the ability of TTR to displace [3H]ryanodine
from RyR2 (Fig. 3,
). Similar results were observed with RyR1 (data
not shown). These results suggest that TTR decreases the binding of
[3H]ryanodine from RyR by direct competition
with [3H]ryanodine for binding site(s) on the
receptors rather than by complexing with accessible sulfhydryl groups,
altering the secondary structure of the receptors and limiting
ryanodine access to its binding site(s). Higher concentrations of
glutathione could not be used because we found that they directly
inhibit binding of [3H]ryanodine to RyR. Such
inhibitory effects of glutathione on [3H]ryanodine binding have been observed in
previous studies (Zable et al., 1997
). Although similar experiments
with 3'-TTR have not yet been performed, there seems little reason to
anticipate that reduced glutathione will alter the ability of this
isoflavonoid to displace [3H]ryanodine from RyRs.
Functional Effects of TTR and 3' TTR on RyR1
Two different experimental protocols with JSRVs were used to evaluate the effects of 3'-TTR and TTR on binding to RyR1 at the multichannel level. These are passive calcium efflux and passive calcium influx assays. Passive calcium efflux assays are particularly useful for assessing the ability of compounds to activate (i.e., open) RyR1. To observe the activating or opening effects of ryanodine or other drugs, vesicles must be loaded with calcium. This requires conditions that coincidentally suppress ryanodine binding. To overcome this problem, high concentrations of drugs are required.
This calcium efflux assay, however, is less applicable for evaluating the ability of compounds to deactivate or close RyR1, especially for compounds with lower affinities and limited aqueous solubility, as seen with TTR and 3'-TTR. To more closely investigate the channel-deactivating effects of 3'-TTR and TTR, we developed and used passive calcium influx assays. In this assay, an intermediate concentration of Ca2+ is used in binding buffer to partially activate (open) RyR1 in the control buffer, accentuating the ability to observe drug-induced alterations in the openness of the channels.
Passive Calcium Efflux Studies: Channel-Activating Effects of TTR and 3'-TTR on RyR1 Are Emphasized in Passive Calcium Efflux Assays. Because several different vesicular preparations were used for these studies, to account quantitatively for variations among preparations, calcium releases were calibrated as a function of maximum-releasable calcium (see Experimental Procedures). The calcium efflux buffer contains approximately 50 nM free calcium, which promotes closure of RyR1 and, as expected, vesicles diluted into this low calcium buffer in the absence of drug release less than 8% of their intraluminal calcium in 3 s (data not shown).
Like ryanodine, TTR and 3'-TTR enhanced calcium release from the vesicles (reflecting activation or opening of RyR1) in a concentration-dependent manner (Fig. 4). Concentration-effect curves of the isoflavonoids were shifted rightward to that of ryanodine. Although ryanodine exhibited an EC50act value of 2.3 µM and triggered release of a maximum of 83% of the intravesicular calcium load at an optimal concentration of 60 µM, 3'-TTR exhibited an EC50act value of 480 µM and at 2 mM triggered complete loss of intravesicular calcium. TTR was slightly less potent than 3'-TTR, exhibiting an EC50act value of 750 µM and at its optimal concentration of 3 mM, released a maximum of 93% intravesicular calcium. Although variations between maximal calcium release by 3'-TTR and TTR were not statistically significant (P < .05), both maxima were significantly greater than that of ryanodine (P < .05). Also, the slopes of the activation curves for 3'-TTR and TTR appeared to be steeper than that of ryanodine, suggesting that both compounds are more effective than ryanodine in activating RyR1.
|
|
Passive Calcium Influx Assays.
To provide a wider margin for
investigating the channel-deactivating effects of TTR, we used passive
calcium influx assays. For this assay, an incubation buffer called
buffer B (250 mM KCl, 15 mM NaCl, 20 mM HEPES, and 25 µM
Ca2+, pH 7.0, at 37°C) was used (Zimanyi et
al., 1991
). As shown in Fig. 5A,
after 2 h of incubation in buffer B, JSRVs bound 23% less
[3H]ryanodine than JSRVs incubated in buffer A
(500 mM KCl, 20 mM Tris·HCl, 200 µM CaCl2, pH
7.0, at 37°C). This difference, significant at P < .05, was secondary to altered calcium concentration. Increasing the
calcium concentration in buffer B from 25 to 200 µM without changing
any other constituents increased [3H]ryanodine
binding by 27%, an amount equivalent to that produced with buffer A. These data confirm that the differences in
[3H]ryanodine binding under these two ionic
conditions is dependent primarily on the concentration of
Ca2+. The apparent affinity of ryanodine for RyR1
under all three buffer conditions was similar
(IC50
6.5 nM; Fig. 5B).
|
|
). After 5 min of preincubation with 60 µM TTR, snapshot calcium
influx had increased by 18% over control. Additional increases in
incubation time resulted in a marked time-dependent decrease in calcium
influx to a nadir of 68% of full opening by 30 min. The deactivation
appears stable for up to 2 h. With 600 µM TTR, only a monotonic,
time-dependent decrease in snapshot calcium influx was evident; any
preceding channel activation could not be discerned (Fig. 6,
).
After 5 min of incubation, calcium influx had already declined by 12%,
revealing only 60% of full channel opening. Additional increases in
incubation times with 600 µM TTR resulted in an additional
time-dependent decrease in snapshot calcium influx. After 2 h, 600 µM TTR had effected almost complete closure of RyR1, allowing
snapshot calcium influx of only 16%.
For comparison, the time-dependent closure of RyR1 channels with the
known calcium channel modulator ryanodine is also shown (Fig. 6,
).
After 5 min of incubation, ryanodine (1 µM) had reduced snapshot
calcium influx by 15% (i.e., it had reduced channel activation to 54%
of maximum). As the preincubation period with 1 µM ryanodine increased, snapshot calcium influx was diminished further, reaching 88% channel deactivation after 2 h of preincubation.
Thus, in calcium efflux and calcium influx assays, both ryanodine and
TTR display channel-activating and -deactivating effects. Activation is
experimentally emphasized in calcium efflux assays, whereas
deactivation is more readily evident in calcium influx assays,
apparently attributable to calcium concentration of the incubation
medium. Although we have not fully characterized the functional effects
of 3'-TTR, its structural similarity to TTR would support its similar
actions on RyR1.
Because the deglycosylated derivative of TTR, tectorigenin, is
commercially available, we sought to extend these studies and perhaps
gain structure-activity insight using this aglycone. We assessed the
affinity of tectorigenin from its ability to compete with 6.7 nM
[3H]ryanodine for binding sites on RyR1 and
RyR2 (Fig. 7). Tectorigenin displaced
[3H]ryanodine from binding sites on RyR1
in a concentration-dependent manner. Near-maximal displacement was
evident at 50 µM tectorigenin; displacement at 100 and 200 µM was
not significantly higher. Thus, tectorigenin apparently competed for
approximately half the available ryanodine binding sites on RyR1.
Whether this is secondary to solubility constraints remains to be
determined. Interestingly, displacement by tectorigenin appeared to be
RyR isoform-specific. At concentrations up to 200 µM, tectorigenin
exerted no ability to displace
[3H]ryanodine from its binding sites on RyR2
(Fig. 7).
|
| |
Discussion |
|---|
|
|
|---|
The principal finding of this study is that TTR isoflavonoids bind to and activate and deactivate striated muscle RyR. Furthermore, the data also support an isoform-specific effect of tectorigenin; it displaced [3H]ryanodine from binding sites on RyR1 but not those on RyR2.
Compared with the molecular structure of ryanodine, TTRs are chemically
simple molecules. Nevertheless, these compounds have been found in
these studies to compete effectively with ryanodine for binding site(s)
on striated muscle RyR. These results suggest that TTR and 3'-TTR
possess unique chemical moieties in common with ryanodine or have
functionalities with similar conformations. Removal of the sugar moiety
on TTR significantly decreases affinity for RyR
(Kd decreased from 6.2 to greater than
100 µM). Thus, the glucose on TTR and 3'-TTR may play an important
role in their ability to bind to RyR. It deserves mention that like
glucose, the
-face of the ryanodine molecule also contains a cluster
of hydroxyl functionalities. Recently, it was shown that oxidation of
the hydroxyls on the C4,
C10, and C12 carbons of the
ryanodine molecule also significantly reduce affinity for RyR
(Jefferies and Casida, 1994
).
Also of interest is the observation that the aglycone tectorigenin
appears to have preferential affinity for RyR1 of fast skeletal
muscles. The unexpected finding is especially intriguing because few
isoform-specific exogenous ligands of RyR have been described.
Imperatoxin activator was initially indicated to be specific for RyR1
(Valdivia et al., 1992
); however, additional studies appear to
contradict that notion (Tripathy et al., 1998
). The early data support
the notion that TTR or analogs thereof may be useful as lead compounds
for ligands with specificity among RyR isoforms. In a recent study
using rat hepatocytes, Tomonaga and coworkers (1992)
found that
tectorigenin was capable of mobilizing calcium from intracellular
stores. However, these investigators found that the structurally
related compounds genestein (also an isoflavone) and quercetin (a
flavone) can also mobilize calcium from intracellular stores. Because
quercetin appears to act on sarco(endo)plasmic reticulum
Ca2+/Mg2+-ATPases, they
inferred that the mode of action of tectorigenin might also be via
inhibition of calcium pumps. This study demonstrates tectorigenin
actions in the absence of calcium pump activity but does not rule out
multiple modes of action on sarco(endo)plasmic reticulum
Ca2+/Mg2+-ATPases.
In previous studies we found that passive calcium efflux assays were
sufficient to assess the functional effects of ryanoids on its binding
to RyR1. However, efflux assays do not present optimal conditions for
assessing channel deactivation effects, especially for those compounds
that possess lower affinities (micromolar range) and have limited
aqueous solubilities. To circumvent this restriction, we modified and
optimized a calcium influx protocol described previously by Sutko and
coworkers (Lattanzio et al., 1987
) to better assess the ability
of TTRs to promote closure of RyR1. Using the latter assay, we observed
that TTR activates (opens) and deactivates (closes) RyR1 in a time and
concentration manner.
In this assay, 1 µM ryanodine also exerts its deactivating effects on
RyR1 after only 5 min of preincubation. These data suggest a fairly
rapid rate of binding of ryanodine to RyR1 under conditions of the
influx assay (low intravesicular calcium and high ambient ionic
strength). It is relevant that two recent studies showed that
micromolar luminal calcium concentrations can increase open probability
of RyR1 activated by ATP and calcium (Herrmann-Frank and Lehmann-Horn,
1996
; Tripathy and Meissner, 1996
).
In this study, we isolated TTRs from ground rhizomes of Acorus
calamus Linn sold under the label "Vacä" (Ugragandha in
Sanskrit, Bacc or Gorbacc in Hindi), and their identities were
established by routine physiochemical methods. However, because TTR and
its congener 3'-TTR have not been described previously as secondary metabolites of Acorus calamus Linn (Araceae family), these
data suggest that the TTR and 3'-TTR we isolated might have originated from other plant sources. If so, likely sources include
Belamchanda and Iris species (Iridiaceae family),
because both are indigenous to the Asian continent and each has been
reported to contain TTR (Agarwal et al., 1984
; Kim, 1999
).
During field collection, Iris rhizomes could be harvested
inadvertently along with Acorus rhizomes because both are
phenotypically similar. Although the plant origin of the TTR and 3'-TTR
used in this study may be thus indeterminate, their presence is
certain, given our physiochemical confirmations. Thus this study
illuminates some vagaries of basic research into herbal preparations.
In summary, these data demonstrate that the isoflavones TTR and 3'-TTR bind to and modulate RyR. Furthermore, the aglycone of TTR, tectorigenin, likewise competes with [3H]ryanodine for binding to RyR, apparently in an isoform-specific manner. Functional studies are underway to evaluate the validity of these observations and to characterize whether isoform specificity of binding is reflected in functional specificity of tectorigenin on RyR1 and RyR2.
| |
Acknowledgments |
|---|
We thank Sangyeol Kwon and Bruce Henry for technical assistance and Phil Wilson and Lydia Gerbig for valuable help with the illustrations.
| |
Footnotes |
|---|
Accepted for publication February 29, 2000.
Received for publication December 28, 1999.
1 This work was supported in part by a grant from the Biomedical Research Committee of the Indiana University School of Medicine (to K.R.B.) and by the Ralph W. and Grace M. Showalter Trust (to H.R.B.).
2 A preliminary report of this study was presented at the 40th Annual Meeting of the Biophysical Society, Baltimore, MD, February 17-21, 1996, and published in abstract form [(1996) Biophys J 70:A281].
Send reprint requests to: Keshore R. Bidasee, Ph.D., Department of Pharmacology and Toxicology, 635 Barnhill Dr., MS A417, Indianapolis, IN 46202-5120. E-mail: kbidase{at}iupui.edu
| |
Abbreviations |
|---|
SR, sarcoplasmic reticulum; RyR, ryanodine receptors; TTR, tectoridin; 3'-TTR, 3'-hydroxy TTR; RyR1, skeletal muscle ryanodine receptor; RyR2, cardiac muscle ryanodine receptor; JSRV, junctional sarcoplasmic reticulum vesicles; TLC, thin-layer chromatography; CV, crude sarcoplasmic reticular membrane vesicles; PMSF, phenylmethyl sulfonyl fluoride; JSRV, junctional SR membrane vesicles; E1c, CHCl3 extract.
| |
References |
|---|
|
|
|---|
-alanyl-
-alanyl ryanodine, a novel photo-affinity ligand for the ryanodine binding site.
J Label Compd Radiopharm
34:
33-47.This article has been cited by other articles:
![]() |
K. R. Bidasee, K. Nallani, Y. Yu, R. R. Cocklin, Y. Zhang, M. Wang, U. D. Dincer, and H. R. Besch Jr. Chronic Diabetes Increases Advanced Glycation End Products on Cardiac Ryanodine Receptors/Calcium-Release Channels Diabetes, July 1, 2003; 52(7): 1825 - 1836. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Bidasee, L. Xu, G. Meissner, and H. R. Besch Jr. Diketopyridylryanodine Has Three Concentration-dependent Effects on the Cardiac Calcium-release Channel/Ryanodine Receptor J. Biol. Chem., April 11, 2003; 278(16): 14237 - 14248. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Bidasee, U. D. Dincer, and H. R. Besch Jr. Ryanodine Receptor Dysfunction in Hearts of Streptozotocin-Induced Diabetic Rats Mol. Pharmacol., December 1, 2001; 60(6): 1356 - 1364. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. D. Dinçer, K. R. Bidasee, S. Güner, A. Tay, A. T. Özçelikay, and V. M. Altan The Effect of Diabetes on Expression of {beta}1-, {beta}2-, and {beta}3-Adrenoreceptors in Rat Hearts Diabetes, February 1, 2001; 50(2): 455 - 461. [Abstract] [Full Text] |
||||
| ||||||||||||